Glembatumumab vedotin
Glembatumumab vedotin (pronunciation: glemba-TOO-muh-mab vee-DOH-tin) is a monoclonal antibody-drug conjugate used in the treatment of certain types of cancer.
Etymology
The name "Glembatumumab vedotin" is derived from the components of the drug. "Glembatumumab" refers to the monoclonal antibody that targets the protein GPNMB, which is overexpressed in certain cancers. "Vedotin" refers to the cytotoxic drug that is attached to the antibody, which works by disrupting the growth of cancer cells.
Usage
Glembatumumab vedotin is used in the treatment of melanoma and breast cancer that overexpress the protein GPNMB. It works by binding to the GPNMB protein on the surface of cancer cells and delivering the cytotoxic drug directly to the cells, causing them to die.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- GPNMB: A protein that is overexpressed in certain types of cancer.
- Cytotoxic drug: A medication that kills cells, especially cancer cells.
- Melanoma: A type of skin cancer.
- Breast cancer: A type of cancer that forms in the cells of the breasts.
See Also
External links
- Medical encyclopedia article on Glembatumumab vedotin
- Wikipedia's article - Glembatumumab vedotin
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski